YLYiqian Lian

Yiqian Lian

*This is an algorithmically generated author record based on publicly available information.

Yiqian Lian has a total of 35 co-authors. Here are the top co-authors by number of shared publications:

  • Aaron Bedermann

    GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States

    1 shared publication
  • Adam Csakai

    GSK, Encoded Library Technologies, NCE Molecular Discovery, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States

    1 shared publication
  • Ann M. Rowley

    GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States

    1 shared publication
  • Colin Macphee

    GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, Hertfordshire, U.K.

    1 shared publication
  • Enoch N. Gao

    GSK, 1250 South Collegeville Road, Collegeville, Pennsylvania 19426, United States

    1 shared publication
  • Gang Yao

    GSK, Encoded Library Technologies, NCE Molecular Discovery, 200 Cambridge Park Drive, Cambridge, Massachusetts 02140, United States

    1 shared publication

Latest Publications

  • Discovery and SAR Study of Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded Library

    by Ann M. Rowley, Gang Yao, Logan Andrews, Aaron Bedermann, Ross Biddulph, Ryan Bingham, Jennifer J. Brady, Rachel Buxton, Ted Cecconie, Rona Cooper, et al.

    Human genetic evidence shows that PDE3B is associated with metabolic and dyslipidemia phenotypes. A number of PDE3 family selective inhibitors have been approved by the FDA for various indications; however, given the undesirable proarrhythmic effects in the heart, selectivity for PDE3B inhibition over closely related family members (such as PDE3A; 48% identity) is a critical consideration for development of PDE3B therapeutics. Selectivity for PDE3B over PDE3A may be achieved in a variety of ways, including properties intrinsic to the compound or tissue-selective targeting. The high (>95%) active site homology between PDE3A and B represents a massive obstacle for obtaining selectivity at the active site; however, utilization of libraries with high molecular diversity in high throughput screens may uncover selective chemical matter. Herein, we employed a DNA-encoded library screen to identify PDE3B-selective inhibitors and identified potent and selective boronic acid compounds bound at the active site.


  • STING Activation and its Application in Immuno-Oncology

    by Yiqian Liana, Kevin J. Duffya, Jingsong Yang

    Recent regulatory approval of several immune checkpoint inhibitors has ushered in a new era of cancer immunotherapies with the promise of achieving a durable response. This represents a paradigm shift in cancer treatment from directly targeting tumor cells to harnessing the power of a patient’s own immune system to destroy them. The cGAS-STING pathway is the major cytosolic dsDNA sensing pathway that plays a pivotal role in the innate antitumor immune response. With a fundamentally different mode of action (MOA) than immune checkpoint modulators, STING activation can potentially enhance tumor immunogenicity and improve patient responses as a single agent or by synergizing with existing anti-cancer drugs. Therefore, there has been intense interest from the pharmaceutical industry and academic institutions in the search for potent STING agonists as immunotherapies in oncology. In this article, we review briefly the cGAS-STING pathway and STING agonists that are in the clinical and preclinical studies, summarize recently disclosed patent applications and published journal articles in the field and cover both cyclic dinucleotide (CDN) analogs and non-nucleic acid derived STING agonists.


  • Product‐Regulation Mechanisms for Fatty Acid Biosynthesis Catalyzed by Mycobacterium smegmatis FAS I

    by Nikolaos Papaioannou, Hwan‐Sung Cheon, Yiqian Lian, Yoshito Kishi